DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
CYBERETIKAGLOBAL FINANCIAL INTELLIGENCE
LIVE
USA Yahoo Finance EN

Amgen Inc. (AMGN) Completes Phase 3 Trial for ABP 206 Opdivo Biosimilar Candidate

Mar 08, 2026 &03500808202631; 16:50 UTC finance.yahoo.com Trending 3/5
Read original on finance.yahoo.com ↗
↗
Positive for markets
Sentiment score: +75/100
High impact Medium-term (weeks)
WHAT THIS MEANS
Amgen has successfully completed Phase 3 trials for ABP 206, its Opdivo biosimilar candidate, representing a significant milestone in the competitive biosimilar market. This achievement strengthens Amgen's pipeline and positions the company for potential regulatory approval and market entry in the oncology biosimilar segment.
AI CONFIDENCE
85% Very high
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
↑
AMGN
AMGNStock
Expected to rise
Successful Phase 3 completion de-risks biosimilar candidate and opens path to regulatory approval and revenue generation
↑
S&P 500
^GSPCIndex
Expected to rise
Positive biotech/pharma sector sentiment from successful clinical trial milestone
PRICE HISTORY
Loading chart...
⚡ SUGGESTED ACTION
Consider accumulating AMGN on any near-term weakness as Phase 3 completion validates the biosimilar strategy. Monitor for FDA approval timeline announcements which could trigger additional upside in the medium term.
KEY SIGNALS
Phase 3 trial completion reduces regulatory riskBiosimilar market opportunity in oncology segmentPotential revenue stream from Opdivo biosimilarCompetitive positioning against other biosimilar developersPipeline advancement supports long-term growth
SECTORS INVOLVED
BiotechnologyPharmaceuticalsHealthcare
Analysis generated on Mar 09, 2026 at 16:03 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

RELATED INTELLIGENCE

Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s,Qualcomm, Rivian, Strategy and More
Yahoo Finance Mar 10, 12:06 Neutral
FDA plans to relax testing rules to encourage biosimilar drugs: report
Seeking Alpha Mar 09, 10:44 Positive
Better Weight Loss Stock: Novo Nordisk Vs. Amgen
Yahoo Finance Mar 08, 18:50 Neutral
Better Weight Loss Stock: Novo Nordisk Vs. Amgen
The Motley Fool Mar 08, 18:30 Neutral
BMW:s vinst högre än väntat
Dagens Industri Mar 12, 06:47 Positive